FindTrial
Sign In

Citicoline as Neuroprotector in Preterm

Efficacy of Citicoline as Neuroprotector in Preterm; A Randomized Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03966170
Enrollment
40
Registered
2019-05-29
Start date
2019-05-01
Completion date
2028-12-31
Last updated
2019-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Term

Brief summary

Citicoline as neuroprotector in preterm

Detailed description

Efficacy of Citicoline as neuroprotector in preterm; A randomized controlled trial.

Interventions

DRUGCiticoline

Citicoline as neuroprotector

DRUGPlacebo oral tablet

placebo drug

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 1 Months
Healthy volunteers
No

Inclusion criteria

* Preterm on CPAP or ventilator

Exclusion criteria

* Multiple congenital anomalies

Design outcomes

Primary

MeasureTime frameDescription
Number of children with affection of the brain6 monthsNumber of children with affection of the brain

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026